Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. Sun Y, Wu C, Xin G, Zhong B, et al. Hepatology 2026;83:1248-1260.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sun Y, Wu C, Xin G, Zhong B, et al. Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. Hepatology 2026;83:1248-1260.
PMID: 40720744